- Home
- RFAI vs INBX Comparison
RFAI vs INBX Comparison
Compare RFAI & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RFAI
- INBX
- Stock Information
- Founded
- RFAI 2024
- INBX 2010
- Country
- RFAI Singapore
- INBX United States
- Employees
- RFAI N/A
- INBX 161
- Industry
- RFAI
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- RFAI
- INBX Health Care
- Exchange
- RFAI NYSE
- INBX Nasdaq
- Market Cap
- RFAI 156.3M
- INBX 168.1M
- IPO Year
- RFAI 2024
- INBX 2020
- Fundamental
- Price
- RFAI N/A
- INBX $11.47
- Analyst Decision
- RFAI
- INBX Hold
- Analyst Count
- RFAI 0
- INBX 1
- Target Price
- RFAI N/A
- INBX N/A
- AVG Volume (30 Days)
- RFAI 8.3K
- INBX 144.3K
- Earning Date
- RFAI 01-01-0001
- INBX 05-08-2025
- Dividend Yield
- RFAI N/A
- INBX 7.40%
- EPS Growth
- RFAI N/A
- INBX N/A
- EPS
- RFAI N/A
- INBX 112.62
- Revenue
- RFAI N/A
- INBX $200,000.00
- Revenue This Year
- RFAI N/A
- INBX N/A
- Revenue Next Year
- RFAI N/A
- INBX N/A
- P/E Ratio
- RFAI $45.33
- INBX $0.10
- Revenue Growth
- RFAI N/A
- INBX N/A
- 52 Week Low
- RFAI $10.00
- INBX $10.80
- 52 Week High
- RFAI $10.43
- INBX $18.95
- Technical
- Relative Strength Index (RSI)
- RFAI N/A
- INBX 34.68
- Support Level
- RFAI N/A
- INBX $10.81
- Resistance Level
- RFAI N/A
- INBX $12.06
- Average True Range (ATR)
- RFAI 0.00
- INBX 1.00
- MACD
- RFAI 0.00
- INBX -0.19
- Stochastic Oscillator
- RFAI 0.00
- INBX 18.52
About RFAI RF ACQUISITION CORP II
RF Acquisition Corp II is a blank check company.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.